The Cape Coral Republican announced his candidacy in Florida’s 19th Congressional District. He will launch the campaign ...

In addition to the receptor used to locate tumor cells, this treatment adds an element that further enhances the immune ...

A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients ...

A patient with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma achieved complete remission following novel in vivo CD19 CAR-T therapy.

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced ...

CAR T-cell product showed promising efficacy and safety in a phase I trial of lymphoma patients who had previously failed ...

New research disentangles the risks for acute kidney injury related to CAR T-cell treatment in non-Hodgkin lymphoma, ...

Genocury launched the in vivo CD19 CAR-T therapy to reach the clinical stage, demonstrating exceptional safety, efficiency ...

Genocury Biotech announces positive results from noval in vivo CD19 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma: Shenzhen, China Friday, May 2, 2025, 15:00 ...